37 results about "Colorectal adenocarcinoma" patented technology

The invention discloses diosgenin hydroxamic acid derivatives and their preparation method and application. Diosgenin is used as a lead compound to prepare a series of hydroxamic acid derivatives through corresponding chemical reactions, and the anti-tumor effect of the derivatives Applications. Pharmacological experiments show that: all synthesized diosgenin hydroxamic acid derivatives are treated with CCK8 method against SW620 (human colon adenocarcinoma cells), H358 (human non-small cell lung cancer cells), HCT‑116 (human colorectal adenocarcinoma cells) and Aspc‑1 (human metastatic pancreatic cancer cells) were tested for antiproliferative activity in vitro. Experimental results show that most of the derivatives have better anti-tumor activity than diosgenin on cells.

The invention relates to a quinoline multi-target kinase inhibitor with antitumor activity and a preparation method thereof. A general structural formula of the compound is shown in a formula (I) described in the specification. In vitro cell experiments verify that the compound provided by the invention has strong in vitro inhibitory activity on five common tumor cell lines, namely human thyroid carcinoma SW579, human hepatic carcinoma HepG2, human lung adenocarcinoma A549, human colorectal adenocarcinoma HCT116 and human gastric carcinoma MKN45, antitumor activities of most of target compounds are better than or equivalent to that of a positive control drug Cabozantinib, and the in vitro cell experiments verify that the compound provided by the invention has strong inhibitory activity on two kinases KDR and MET, so that the compound provided by the invention has a broad application prospect in preparation of a new antitumor drug.

The invention provides a human colorectal adenocarcinoma tumor cell line as well as a preparation method and an application thereof. The cell line P6C of human colorectal adenocarcinoma tumor stem cell line has the preservation number of CGMCC No.5558. The preparation method comprises the following steps of: 1) separating original colon cancer stem cells; 2) culturing the primary colon cancer stem cells in vitro; 3) culturing and identifying the colon cancer stem cells; and 4) separating and culturing the obtained colon cancer stem cells according to the same method in the steps 1), 2) and 3) to screen and express the tumor stem cell of CD44 membrane protein. The cell line can be applied in the preparation of the medicine for inducing tumour formation, a medicine for tumor metastasis and medicines for screening antituvmorigenesis, anti-tumor growth and anti-tumor metastasis.